155650-56-9

Basic information

• Product Name: 2H-Pyran-4-carbonitrile, tetrahydro-4-methoxy-
• Synonyms: 2H-Pyran-4-carbonitrile, tetrahydro-4-methoxy-
• CAS NO: 155650-56-9
• Molecular Formula: C₇H₁₁NO₂
• Molecular Weight: 141.17
• Mol File: 155650-56-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2H-Pyran-4-carbonitrile, tetrahydro-4-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-4-carbonitrile, tetrahydro-4-methoxy-(155650-56-9)
• EPA Substance Registry System: 2H-Pyran-4-carbonitrile, tetrahydro-4-methoxy-(155650-56-9)

Safety Data

• Hazardous Substances Data: 155650-56-9(Hazardous Substances Data)

Upstream product

• 28218-71-5 4,4-dimethoxytetrahydro-4H-pyran 
• 119072-55-8 tert-butylisonitrile 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 1269755-10-3 (4-methoxytetrahydro-2H-pyran-4-yl)methanamine 
• 1270077-00-3 6-(benzyloxy)-3-fluoro-N-((4-methoxytetrahydro-2H-pyran-4-yl)methyl)pyridin-2-amine 
• 1010836-49-3 4-methoxytetrahydro-2H-pyran-4-carboxylic acid 
• 175982-76-0 4-methoxytetrahydro-2H-pyran-4-carbaldehyde 
• 175982-78-2 1-(4-Methoxy-tetrahydro-pyran-4-yl)-ethanone 

Relevant articles and documents

Efficient preparation of 4-methoxy-5,6-dihydro-2H-pyran

We report the efficient synthesis of 4-methoxy-5,6-dihydro-2H-pyran (MDHP) via the TiCl4 driven elimination of MeOH from 4,4-dimethoxytetrahydropyran. The previous difficulty of preparing MDHP restricted the wider use of 4-methoxytetrahydropyran-4-yl (MTHP) acyclic acetals, which have desirable protecting group properties when compared to more commonly used MOM- and THP-acetals. The behaviour of the elimination on related acetals is also examined.

PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I, and pharmaceutical compositions comprising such compounds

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a pyrimidine compound of formula (I): wherein one of X and Y but not both is N, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tantomers, diastereomers, deuterated versions, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds

PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.

HETEROARYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor

IMIDAZOLE DERIVATIVE

A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.